Henrietta Wellington
Overview
Explore the profile of Henrietta Wellington including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
242
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wagen A, Coath W, Keshavan A, James S, Parker T, Lane C, et al.
Lancet Healthy Longev
. 2022 Sep;
3(9):e607-e616.
PMID: 36102775
Background: A neuroimaging-based biomarker termed the brain age is thought to reflect variability in the brain's ageing process and predict longevity. Using Insight 46, a unique narrow-age birth cohort, we...
2.
Williams T, Holdsworth K, Nicholas J, Eshaghi A, Katsanouli T, Wellington H, et al.
Neurol Neuroimmunol Neuroinflamm
. 2022 Jan;
9(2).
PMID: 35031587
Background And Objectives: Improved biomarkers of neuroprotective treatment are needed in progressive multiple sclerosis (PMS) to facilitate more efficient phase 2 trial design. The MS-STAT randomized controlled trial supported the...
3.
Keshavan A, Wellington H, Chen Z, Khatun A, Chapman M, Hart M, et al.
Alzheimers Dement (Amst)
. 2021 Feb;
13(1):e12131.
PMID: 33598527
Introduction: We assessed the concordance of cerebrospinal fluid (CSF) amyloid beta (Aβ) and tau measured on the fully automated Lumipulse platform with pre-symptomatic Alzheimer's disease (AD) pathology on amyloid positron...
4.
Keshavan A, Wellington H, Chen Z, Khatun A, Chapman M, Hart M, et al.
Alzheimers Dement (Amst)
. 2020 Oct;
12(1):e12097.
PMID: 32999915
Introduction: We assessed the concordance of cerebrospinal fluid (CSF) amyloid beta (Aβ) and tau measured on the fully automated Lumipulse platform with pre-symptomatic Alzheimer's disease (AD) pathology on amyloid positron...
5.
Toombs J, Foiani M, Wellington H, Paterson R, Arber C, Heslegrave A, et al.
Alzheimers Dement (Amst)
. 2018 May;
10:311-321.
PMID: 29780875
Introduction: We tested the hypothesis that the amyloid β (Aβ) peptide ratios are more stable than Aβ alone when biofluids are exposed to two preanalytical conditions known to modify measurable...
6.
Wellington H, Paterson R, Suarez-Gonzalez A, Poole T, Frost C, Sjobom U, et al.
Ann Clin Transl Neurol
. 2018 Feb;
5(2):162-171.
PMID: 29468177
Objective: To assess whether high levels of cerebrospinal fluid neurogranin are found in atypical as well as typical Alzheimer's disease. Methods: Immunoassays were used to measure cerebrospinal fluid neurogranin in...
7.
Bergstrom P, Agholme L, Nazir F, Satir T, Toombs J, Wellington H, et al.
Sci Rep
. 2016 Jul;
6:29200.
PMID: 27383650
Amyloid precursor protein (APP) and its cleavage product amyloid β (Aβ) have been thoroughly studied in Alzheimer's disease. However, APP also appears to be important for neuronal development. Differentiation of...
8.
Wellington H, Paterson R, Portelius E, Tornqvist U, Magdalinou N, Fox N, et al.
Neurology
. 2016 Jan;
86(9):829-35.
PMID: 26826204
Objective: To assess the specificity of the dendritic protein neurogranin (Ng) in CSF from patients with a broad range of neurodegenerative diseases including a variety of dementias, tauopathies, and synucleinopathies....